Pharmaceuticals company Sai Life Science announced Q2FY26 results Revenue from Operations was Rs 537 crore for Q2FY26 compared to Rs 396 crore in Q2FY25, an increase of 36% driven by strong growth both in CRO and CDMO services. EBITDA stood at Rs 156 crore for Q2FY26 compared to Rs 109 crore in Q2FY25, an increase of 43%. PAT stood at Rs 84 crore for Q2FY26 compared to Rs 42 crore in Q2FY25, an increase of 100% Krishna Kanumuri, Managing Director & CEO, Sai Life Sciences, said: “We are pleased to report another strong quarter, supported by healthy demand across our discovery, development, and manufacturing services. The performance was driven by consistent execution, growing client relationships, and continued traction in late-stage and commercial programs. As the industry evolves toward more complex and diversified science, we continue to invest in new modalities, advanced technologies, and capacity expansion to strengthen our long-term competitiveness. These investments are enabling us to address a broader range of client needs, enhance efficiency across the value chain, and build deeper scientific capabilities for the future. Looking ahead, our priorities remain centered on scaling responsibly, advancing technology-led innovation, and deepening client collaborations. With a strong foundation, expanding infrastructure, and scientific excellence at the core of our strategy, Sai Life Sciences is well positioned to deliver sustainable growth and long-term value." Siva Chittor, Whole-time Director & Chief Financial Officer, Sai Life Sciences, said: “We sustained our positive momentum this quarter, maintaining growth across our business and keeping Sai Life Sciences firmly on track toward its long-term aspirations. Total revenue for Q2FY26 stood at Rs 537 crore, up 36% year-on-year, driven by healthy performance across both the CRO and CDMO services. EBITDA for the quarter was Rs 156 crore, with margins at 29%, supported by improved operating leverage, better utilization and continued cost discipline. We incurred capex of Rs 248 crore during H1, primarily directed toward expanding our R&D; capacity, and advancing our offerings in new modalities and technologies. These investments are aligned with our strategy to enhance scientific depth and build scalable capacity to support future growth. We remain focused on maintaining financial discipline, driving margin improvement, and deploying capital effectively to sustain long-term, profitable growth.” Result PDF
Pharmaceuticals company Sai Life Science announced Q1FY26 results Revenue from Operations was Rs 496 crore for Q1FY26 compared to Rs 280 crore in Q1FY25, an increase of 77% driven primarily by strong growth in CDMO segment. EBITDA stood at Rs 125 crore. for Q1FY26 compared to Rs 31 crore in Q1FY25. an increase of 305%. EBITDA margin expanded by 14% YoY to 25% in Q1FY26. PAT for Q1FY26 stood at Rs 60 crore. Invested Rs 134 crore in capital expenditure during Q1FY26. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said: “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. This momentum reflects the growing trust and deepening engagement we share with our global pharma clients' relationships that continue to anchor us through macroeconomic uncertainty and broader industry cycles. As the nature of innovation in drug development evolves, we are proactively investing in the infrastructure and scientific depth required to support complex and emerging modalities. During the quarter, we inaugurated new Biology Labs that significantly strengthen our Integrated Discovery platform and enhance our ability to handle greater molecular complexity. We also broke ground on a new Process R&D; Block at our Hyderabad campus, which will nearly double our process R&D; capacity and bring in next generation, data-rich process capabilities to handle increasingly complex molecules. These are deliberate steps in our journey to be the partner of choice for advancing innovation in complex science. We remain committed to enabling our clients’ aspirations with speed, scientific rigor, and an unrelenting focus on quality." Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences, said:” We are pleased to report a robust performance for Q1FY26, marked by strong growth across our Discovery and CDMO businesses. Total revenue for the quarter stood at Rs 496 crore, up 77% YoY, led by 113% growth in our CDMO segment and a 38% rise in Discovery revenues, enabled by deeper engagement with global clients. We recorded EBITDA of Rs 125 crore, growing 305% YoY, with margins expanding to 25%, an improvement of 14% YoY driven by operating leverage, scale efficiencies, and improved productivity across our sites. During the quarter, we invested Rs 134 crore in capex. This includes investments in new R&D; infrastructure and process development capabilities, enabling us to support complex and emerging modalities such as peptides, ADCs, and oligonucleotides. As we look ahead, we remain optimistic about our growth trajectory. With a strong foundation in place, we are focused on scaling execution, strengthening client partnerships, and investing in technology and talent to deliver sustained performance and long-term value.” Result PDF
Pharmaceuticals company Sai Life Science announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations was Rs 580 crore for Q4FY25 compared to Rs 439 crore in Q4FY24, an increase of 32% EBITDA stood at Rs 161 crore. for Q4FY25 compared to Rs 124 crore. in Q4FY24, an increase of 30% PAT stood at Rs 88 crore. for Q4FY25 compared to Rs 56 crore. in Q4FY24, an increase of 57% FY25 Financial Highlights: Revenue from Operations was Rs 1,695 crore for FY25 compared to Rs 1,465 crore in FY24, an increase of 16% EBITDA stood at Rs 425 crore. for FY25 compared to Rs 300 crore in FY24. an increase of 42% PAT stood at Rs 170crore. for FY25 compared to Rs 83 crore in FY24, an increase of 105% Commenting on the performance during the quarter, Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said, “We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners. One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics. With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to tap into new growth opportunities. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients. As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders.” Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences added, ” We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned Rs 720 crore debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26. Capex for the year stood at Rs 408 crore, focused on enhancing our manufacturing footprint and expanding discovery capabilities. We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders.” Result PDF